NumerixS Investment Technologies’s Revance Therapeutics, Inc. RVNC Stock Holding History

NumerixS Investment Technologies’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,600	Closed	-$24K	–	1334
2020 Q1	$24K	Buy	+1,600	New	+$33.1K	0.01%	771
2019 Q2	–	Sell	-2,600	Closed	-$42K	–	1398
2019 Q1	$42K	Buy	+2,600	New	+$45.1K	0.01%	1015
2018 Q4	–	Sell	-400	Closed	-$10K	–	1441
2018 Q3	$10K	Buy	+400	New	+$10.9K	﹤0.01%	1137
2018 Q2	–	Sell	-600	Closed	-$18K	–	1395
2018 Q1	$18K	Buy	+600	New	+$19.3K	﹤0.01%	936

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

NumerixS Investment Technologies's RVNC Position: Q2 2020 in Review

NumerixS Investment Technologies sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2020, closing a stake of 1,600 shares — an estimated $24K sold.

NumerixS Investment Technologies first reported a position in RVNC in Q1 2018 and held it in 4 quarters. The position peaked at $42K in Q1 2019. 144 funds tracked by Wall St. Rank hold RVNC as of Q2 2020.

NumerixS Investment Technologies reported no remaining Revance Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
NumerixS Investment Technologies sold 1,600 Revance Therapeutics, Inc. shares in Q2 2020, an estimated $24K.
NumerixS Investment Technologies first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 4 quarters.
NumerixS Investment Technologies's Revance Therapeutics, Inc. position peaked at $42K in Q1 2019.
144 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2020.

Based on NumerixS Investment Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.